non small cell lung cancer
Conditions
Interventions
Case series:doxorubicin-eluting beads
Sponsors
The Affiliated Hospital of Hu'nan University of Chinese Medicine
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1) the age is above 18 years, and the sex is not limited; 2) NSCLC was diagnosed by pathological and/or cytological examination under fiberoptic bronchoscope or CT-guided puncture biopsy. Stages III and IV of international lung cancer were unresectable, systemic chemotherapy failed, gene testing (EGFR, ALK) negative or refusal / incompetence to use targeted drugs; 3) the estimated survival period is longer than 6 months; 4) the ECOG (PS) score is less than 2; 5) Laboratory examination: white blood cell (> 3 *109/L), platelet count (> 60 *109/L), hemoglobin (> 85g/L), lymphocyte count (> 15%), total bilirubin (> 100mmol/L), ALT and AST (> 5 times) and serum creatinine (> 1.5 times); 6) contraindication of non vascular interventional therapy; 7) Female pregnancy tests of reproductive age must be negative, or male and female patients must agree to use effective contraceptives during treatment and within the following year; 8) the patients signed the informed consent to participate in the trial study, and they were able to follow up and have good compliance.
Exclusion criteria
Exclusion criteria: 1) surgical tumor resection or local ablation can be performed; 2) coagulation function is poor INR > 1.5 or undergoing anticoagulation therapy or known hemorrhagic diseases; 3) unstable coronary heart disease or recent myocardial infarction (less than one year); 4) recent infections need antibiotic treatment; 5) primary malignant tumors with other organs; 6) DSA showed that the feeding artery of the tumor contained anterior spinal artery and/or esophageal artery and could not be avoided; the bronchial artery was too thin and the intubation was unsuccessful; the arteriovenous fistula could not be embolized by microspheres; 7) can cause the subjects to fail to follow the research plan or even endanger the patient's safety complications or social environment.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Objective response rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| Progression free survival;1 and 2 year survival rates;Improvement of pulmonary function;Improvement of living conditions;Safety evaluation; | — |
Countries
China
Contacts
Public ContactDeng Xiangsheng
The Affiliated Hospital of Hu'nan University of Chinese Medicine
Outcome results
None listed